Strong results announced for new LRRK2 inhibitor clinical trial for Parkinson’s

News

Author: Parkinson's Life editorsPublished: 10 January 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

Conceptual illustration of neuron cells with glowing link knots. Synapse and Neuron cells sending electrical chemical signals. Neuron of Interconnected neurons with electrical pulses, 3D rendering

The pharmaceutical company Denali Therapeutics has announced strong positive results from the first in-human LRRK2 inhibitor clinical trial.

The treatment lowers LRRK2 protein activity in body cells, which could ultimately have the potential to slow – or stop – Parkinson’s progression.

The small molecule inhibitor of LRRK2, called DNL201, achieved an average of more than 90% inhibition of LRRK2 kinase activity observed at peak.

Dr Ryan Watts, PhD, CEO of Denali Therapeutics, said: “Mutations in LRRK2 are a major risk factor for Parkinson’s disease. Targeting this degenogene represents a promising approach to develop disease modifying medicines for patients suffering from this terrible disease.”

He continued: “By restoring LRRK2 activity to normal levels, we believe we can reverse lysosomal dysfunction, which could potentially benefit both patients with LRRK2 mutations, as well as idiopathic Parkinson’s disease patients who exhibit lysosomal dysfunction.”

Go Back

Share this story

Comments


Related articles


Tonya Walker behind the scenes lead

Perspectives

Tonya’s trends: timing is everything when managing Parkinson’s symptoms

How I juggle medication schedules with my busy lifestyle

READ MORE
The UK Parkinson's Football Team

Interviews

The road to Copenhagen: The UK Parkinson’s Football Team

We talk to team captain Charlie Appleyard

READ MORE

Resources & Tools

Parkinson’s podcast: ‘New Neurons for Old’ – interview with Dr Roger Barker

The controversial history of foetal tissue and stem cell therapies

READ MORE